BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly

Eric Palmer

is one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb has sold it in the U.S. But no longer fits in the sweet spot for Bristol-Myers which is hot for immuno-oncology right now and so is turning marketing of the colorectal cancer drug to others. In the U.S. that is Eli , whose ImClone unit developed the cancer drug and put the marketing deal in place before bought ImClone some years back.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS